$7.36
0.182.51%
At close: -
$7.36
0.000.00%
After Hours: Apr 17, 4:00 PM EDT
Comments
Loading...
Amneal Pharmaceuticals Stock Guidance | NASDAQ:AMRX | Benzinga
Amneal Pharmaceuticals issues guidance on future EPS and revenue, giving investors insight into how much the company expects to earn in upcoming periods.
| Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 02/28/2025 | AMRX | Amneal Pharmaceuticals | FY | 2025 | $0.65 | $0.70 | $0.71 | $3.00B | $3.10B | $2.92B | Get Alert |
| 01/15/2025 | AMRX | Amneal Pharmaceuticals | FY | 2024 | $0.57 | $0.63 | $0.61 | $2.70B | $2.80B | $2.77B | Get Alert |
| 11/08/2024 | AMRX | Amneal Pharmaceuticals | FY | 2024 | $0.57 | $0.63 | $0.60 | $2.70B | $2.80B | $2.76B | Get Alert |
| 08/09/2024 | AMRX | Amneal Pharmaceuticals | FY | 2024 | $0.57 | $0.63 | $0.61 | $2.70B | $2.80B | $2.65B | Get Alert |
| 05/03/2024 | AMRX | Amneal Pharmaceuticals | FY | 2024 | $0.53 | $0.63 | $0.58 | $2.55B | $2.65B | $2.61B | Get Alert |
| 03/01/2024 | AMRX | Amneal Pharmaceuticals | FY | 2024 | $0.53 | $0.63 | $0.60 | $2.55B | $2.65B | $2.58B | Get Alert |
| 11/07/2023 | AMRX | Amneal Pharmaceuticals | FY | 2023 | $0.51 | $0.58 | $0.55 | $2.37B | $2.42B | $2.37B | Get Alert |
| 10/23/2023 | AMRX | Amneal Pharmaceuticals | FY | 2023 | $0.51 | $0.58 | $0.55 | $2.37B | $2.42B | $2.37B | Get Alert |
| 10/23/2023 | AMRX | Amneal Pharmaceuticals | Q3 | 2023 | — | — | — | $610.00M | $620.00M | $585.69M | Get Alert |
| 08/04/2023 | AMRX | Amneal Pharmaceuticals | FY | 2023 | $0.45 | $0.55 | $0.47 | $2.30B | $2.40B | $2.32B | Get Alert |
| 05/05/2023 | AMRX | Amneal Pharmaceuticals | FY | 2023 | $0.40 | $0.50 | $0.50 | $2.25B | $2.35B | $2.32B | Get Alert |
| 04/17/2023 | AMRX | Amneal Pharmaceuticals | FY | 2023 | $0.40 | $0.50 | $0.50 | $2.25B | $2.35B | $2.31B | Get Alert |
| 04/17/2023 | AMRX | Amneal Pharmaceuticals | Q1 | 2023 | — | — | — | $550.00M | $560.00M | $529.47M | Get Alert |
| 03/02/2023 | AMRX | Amneal Pharmaceuticals | FY | 2023 | $0.40 | $0.50 | $0.77 | $2.25B | $2.35B | $2.31B | Get Alert |
| 01/10/2023 | AMRX | Amneal Pharmaceuticals | FY | 2022 | $0.65 | $0.70 | $0.66 | $2.15B | $2.25B | $2.18B | Get Alert |
| 11/04/2022 | AMRX | Amneal Pharmaceuticals | FY | 2022 | $0.65 | $0.70 | $0.68 | $2.15B | $2.25B | $2.20B | Get Alert |
| 08/05/2022 | AMRX | Amneal Pharmaceuticals | FY | 2022 | $0.65 | $0.70 | $0.81 | $2.15B | $2.25B | $2.17B | Get Alert |
| 05/04/2022 | AMRX | Amneal Pharmaceuticals | FY | 2022 | $0.80 | $0.85 | $0.84 | $2.15B | $2.25B | $2.19B | Get Alert |
| 03/02/2022 | AMRX | Amneal Pharmaceuticals | FY | 2022 | $0.80 | $0.85 | $0.90 | $2.15B | $2.25B | $2.17B | Get Alert |
| 01/11/2022 | AMRX | Amneal Pharmaceuticals | FY | 2021 | $0.78 | $0.88 | $0.88 | $2.10B | $2.10B | $2.10B | Get Alert |
| 11/03/2021 | AMRX | Amneal Pharmaceuticals | FY | 2021 | $0.78 | $0.88 | $0.88 | $2.10B | $2.10B | $2.14B | Get Alert |
| 08/09/2021 | AMRX | Amneal Pharmaceuticals | FY | 2021 | $0.70 | $0.85 | $0.82 | $2.10B | $2.20B | $2.12B | Get Alert |
| 05/07/2021 | AMRX | Amneal Pharmaceuticals | FY | 2021 | $0.70 | $0.85 | $0.78 | $2.10B | $2.20B | $2.14B | Get Alert |
| 02/26/2021 | AMRX | Amneal Pharmaceuticals | FY | 2021 | $0.70 | $0.85 | $0.71 | $2.10B | $2.20B | $2.06B | Get Alert |
| 01/12/2021 | AMRX | Amneal Pharmaceuticals | FY | 2020 | $0.55 | $0.65 | $0.62 | $1.95B | $2.00B | $1.99B | Get Alert |
| 11/06/2020 | AMRX | Amneal Pharmaceuticals | FY | 2020 | $0.55 | $0.65 | $0.59 | $1.95B | $2.00B | $1.93B | Get Alert |
| 08/06/2020 | AMRX | Amneal Pharmaceuticals | FY | 2020 | $0.45 | $0.60 | $0.56 | $1.88B | $1.98B | $1.91B | Get Alert |
FAQ
What is the most recent guidance for Amneal Pharmaceuticals (AMRX)?
The most recent guidance for Amneal Pharmaceuticals (AMRX) was reported on February 28, 2025 for the full year 2025. The company provided earnings per share guidance in the range of $0.65 to $0.70, compared to the estimated EPS of $0.71. Additionally, Amneal Pharmaceuticals forecasted revenue between $3.00B and $3.10B for the quarter.
Browse guidance and forecast on all stocks.
